Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 10,000 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Exelixis Trading Up 0.9 %

EXEL stock opened at $38.65 on Thursday. The stock has a market cap of $10.82 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The stock has a 50-day moving average price of $34.81 and a two-hundred day moving average price of $31.91. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $39.30.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EXEL. Truist Financial raised their target price on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Stifel Nicolaus raised their price objective on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. Citigroup upped their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research report on Thursday, February 13th. Finally, Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $30.00 to $40.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Institutional Trading of Exelixis

Institutional investors have recently made changes to their positions in the business. Seizert Capital Partners LLC grew its position in Exelixis by 8.0% in the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp bought a new position in shares of Exelixis in the 3rd quarter valued at about $4,396,000. CWA Asset Management Group LLC bought a new stake in Exelixis during the third quarter worth about $577,000. Finally, Blue Trust Inc. boosted its position in Exelixis by 134.7% during the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 8,208 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.